Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
refametinib + sorafenib
- Development stage
- Phase 2
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Refametinib (BAY86-9766) is an oral, allosteric inhibitor of MEK1/2 (mitogen-activated protein kinase kinases 1 and 2), developed for the treatment of cancers driven by aberrant MAPK pathway signaling. Sorafenib is a multikinase inhibitor that targets several tyrosine protein kinases including RAF kinases and vascular endothelial growth factor receptors (VEGFR). The combination of refametinib and sorafenib has been investigated primarily in hepatocellular carcinoma (HCC), particularly in patients with RAS mutations. Preclinical studies demonstrated synergistic antitumor activity through dual inhibition of the MAPK pathway and angiogenesis. Clinical trials showed that this combination had antitumor activity but required frequent dose modifications due to adverse events[2][4][5]. Refametinib was developed by Bayer.
- Brand names
- Nexavar
- Other names
- refametinib + sorafenib
02
Targets
BRAF (B-Raf proto-oncogene, serine/threonine kinase)FLT3 (Fms related receptor tyrosine kinase 3)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)PDGFRB (Platelet-derived growth factor receptor beta)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)RAF1 (c-Raf-1 (Y340D/Y341D))
Beyond the preview
Go deeper on refametinib + sorafenib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on refametinib + sorafenib.